Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who are willing to take part in the study
- People who have cancer and are receiving treatment before surgery (neoadjuvant), after surgery (adjuvant), or as ongoing maintenance treatment
- People who are being treated with a type of cancer drug called an immune checkpoint inhibitor (ICI) — either on its own or combined with other cancer treatments such as targeted therapy, chemotherapy, or radiotherapy — whether as a first treatment or after previous treatment that included ICIs
- People who have received at least one dose of an immune checkpoint inhibitor
- People who have developed liver inflammation (hepatitis) after starting treatment, shown by specific blood test results being significantly above normal levels (confirm with trial site for exact values)
- People whose liver inflammation is classified as severe (grade 3 or 4) according to standard medical grading
Who may not be able to join:
- People whose liver inflammation has a cause other than their cancer treatment — for example, a viral infection, an autoimmune condition, reduced blood flow to the liver, heavy alcohol use, or a condition called Wilson's disease
- People who are not able to communicate their agreement or non-objection to taking part
- People who are in custody, under legal guardianship or curatorship, or in an emergency medical situation
- People who are not covered by a social security or healthcare system (confirm with trial site regarding specific coverage requirements)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: Phone: +33467330224
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ratio cholestatic phenotype, cytolytic phenotype and mixed phenotype
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.